Loading...
Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone
Multiple myeloma is a common plasma cell malignancy with a median overall survival of fewer than 10 years. Proteasome inhibitors comprise an important part of the treatment regimen for this disease. The present study reports the case of a 57-year-old man who experienced a second relapse of multiple...
Na minha lista:
| Udgivet i: | World J Oncol |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Elmer Press
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7011904/ https://ncbi.nlm.nih.gov/pubmed/32095187 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/wjon1241 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|